These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
397 related articles for article (PubMed ID: 12828654)
21. Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-kappa B ligand) ratio and serum interleukin-6 in male mice. Lindberg MK; Erlandsson M; Alatalo SL; Windahl S; Andersson G; Halleen JM; Carlsten H; Gustafsson JA; Ohlsson C J Endocrinol; 2001 Dec; 171(3):425-33. PubMed ID: 11739008 [TBL] [Abstract][Full Text] [Related]
22. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Chen G; Sircar K; Aprikian A; Potti A; Goltzman D; Rabbani SA Cancer; 2006 Jul; 107(2):289-98. PubMed ID: 16752412 [TBL] [Abstract][Full Text] [Related]
23. Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat. Silvestrini G; Ballanti P; Patacchioli F; Leopizzi M; Gualtieri N; Monnazzi P; Tremante E; Sardella D; Bonucci E J Mol Histol; 2005 Feb; 36(1-2):59-67. PubMed ID: 15704000 [TBL] [Abstract][Full Text] [Related]
24. Age of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK. Evans CE; Mylchreest S; Andrew JG BMC Musculoskelet Disord; 2006 Mar; 7():21. PubMed ID: 16519799 [TBL] [Abstract][Full Text] [Related]
26. Dual regulation of osteoclast differentiation by periodontal ligament cells through RANKL stimulation and OPG inhibition. Kanzaki H; Chiba M; Shimizu Y; Mitani H J Dent Res; 2001 Mar; 80(3):887-91. PubMed ID: 11379890 [TBL] [Abstract][Full Text] [Related]
27. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. Lee CK; Lee EY; Chung SM; Mun SH; Yoo B; Moon HB Arthritis Rheum; 2004 Dec; 50(12):3831-43. PubMed ID: 15593184 [TBL] [Abstract][Full Text] [Related]
28. Expression and role of RANKL in periodontal ligament cells during physiological root-resorption in human deciduous teeth. Fukushima H; Kajiya H; Takada K; Okamoto F; Okabe K Eur J Oral Sci; 2003 Aug; 111(4):346-52. PubMed ID: 12887401 [TBL] [Abstract][Full Text] [Related]
29. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. Ikeda T; Utsuyama M; Hirokawa K J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864 [TBL] [Abstract][Full Text] [Related]
30. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Haynes DR; Crotti TN; Loric M; Bain GI; Atkins GJ; Findlay DM Rheumatology (Oxford); 2001 Jun; 40(6):623-30. PubMed ID: 11426018 [TBL] [Abstract][Full Text] [Related]
31. Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. Lubberts E; Oppers-Walgreen B; Pettit AR; Van Den Bersselaar L; Joosten LA; Goldring SR; Gravallese EM; Van Den Berg WB Arthritis Rheum; 2002 Nov; 46(11):3055-64. PubMed ID: 12428250 [TBL] [Abstract][Full Text] [Related]
32. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637 [TBL] [Abstract][Full Text] [Related]
33. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. Crotti TN; Smith MD; Findlay DM; Zreiqat H; Ahern MJ; Weedon H; Hatzinikolous G; Capone M; Holding C; Haynes DR Biomaterials; 2004 Feb; 25(4):565-73. PubMed ID: 14607494 [TBL] [Abstract][Full Text] [Related]
34. Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease. Valverde P; Kawai T; Taubman MA J Bone Miner Res; 2004 Jan; 19(1):155-64. PubMed ID: 14753747 [TBL] [Abstract][Full Text] [Related]
35. Runx-2 is not essential for the vitamin D-regulated expression of RANKL and osteoprotegerin in osteoblastic cells. Notoya M; Otsuka E; Yamaguchi A; Hagiwara H Biochem Biophys Res Commun; 2004 Nov; 324(2):655-60. PubMed ID: 15474477 [TBL] [Abstract][Full Text] [Related]
36. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Huang L; Xu J; Wood DJ; Zheng MH Am J Pathol; 2000 Mar; 156(3):761-7. PubMed ID: 10702390 [TBL] [Abstract][Full Text] [Related]
37. Osteoprotegerin and rank ligand expression in prostate cancer. Brown JM; Corey E; Lee ZD; True LD; Yun TJ; Tondravi M; Vessella RL Urology; 2001 Apr; 57(4):611-6. PubMed ID: 11306358 [TBL] [Abstract][Full Text] [Related]
38. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. Park HR; Min SK; Cho HD; Kim DH; Shin HS; Park YE J Korean Med Sci; 2003 Aug; 18(4):541-6. PubMed ID: 12923331 [TBL] [Abstract][Full Text] [Related]
39. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. Palmqvist P; Persson E; Conaway HH; Lerner UH J Immunol; 2002 Sep; 169(6):3353-62. PubMed ID: 12218157 [TBL] [Abstract][Full Text] [Related]
40. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. Lubberts E; van den Bersselaar L; Oppers-Walgreen B; Schwarzenberger P; Coenen-de Roo CJ; Kolls JK; Joosten LA; van den Berg WB J Immunol; 2003 Mar; 170(5):2655-62. PubMed ID: 12594294 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]